CMT
Clinical trials for CMT explained in plain language.
Never miss a new study
Get alerted when new CMT trials appear
Sign up with your email to follow new studies for CMT, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Gene therapy injection tested for rare nerve disease
Disease control CompletedThis early-phase trial tested the safety of a gene therapy called Engensis (VM202) in 12 adults with Charcot-Marie-Tooth disease type 1A (CMT1A), a genetic nerve disorder that causes muscle weakness. Participants received multiple injections into their leg muscles and were monito…
Matched conditions: CMT
Phase: PHASE1, PHASE2 • Sponsor: Helixmith Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC
-
New drug shows promise for nerve disease that affects walking
Symptom relief CompletedThis study tested a new medicine called NMD670 in 81 adults with Charcot-Marie-Tooth disease types 1 and 2. Participants took either the drug or a placebo twice daily for 21 days. The main goal was to see if the drug could improve walking distance in 6 minutes. The study also che…
Matched conditions: CMT
Phase: PHASE2 • Sponsor: NMD Pharma A/S • Aim: Symptom relief
Last updated Jun 27, 2026 07:57 UTC
-
Could a single DNA test solve the mystery of rare brain diseases in kids?
Knowledge-focused CompletedThis study looked at whether whole genome sequencing (a complete read of a person's DNA) can help diagnose leukodystrophies, a group of rare brain diseases that are hard to identify. Researchers enrolled 236 children with white matter abnormalities on brain scans but no known gen…
Matched conditions: CMT
Sponsor: Children's Hospital of Philadelphia • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:56 UTC